# DataMEDS AI, Inc. (MEDS)

> Source: Nexqual · https://nexqual.com/MEDS · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, DataMEDS AI, Inc. (MEDS), nexqual.com/MEDS" · informational, not investment advice.

**Price:** USD 2.23 (-3.04% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 2.3 · day 2.19–2.36 · 52w 0.82–46.5 · market cap $10.1M · NCM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $8.0M, net income -$88.3M (-1100.3% margin) (SEC filings).
- Analysts: None.
- Total return with dividends: 1Y -96.1% vs S&P 500 +13.4%; 5Y -98.8% vs S&P 500 +76.9%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|
| Revenue | — | $18.1M | $23.3M | $8.0M |
| Gross profit | — | $1.8M | -$6.4M | — |
| Operating income | -$2.9M | -$6.1M | -$93.7M | -$70.3M |
| Net income | -$2.9M | -$6.9M | -$101M | -$88.3M |
| EPS (diluted) | -$3.00 | -$7.50 | -$71.50 | — |
| Gross margin | — | 9.7% | -27.5% | — |
| Operating margin | — | -33.9% | -401.7% | -875.7% |
| Net margin | — | -37.8% | -433.9% | -1100.3% |
| Revenue growth | — | — | +28.7% | — |
| Cash + short-term investments | $1K | $1.0M | $43K | — |
| Total debt | — | $23.4M | $23.5M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 1.3x · EV/Sales 4.9x · Earnings yield -876.60% · Net debt $29.3M · EV $39.4M

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2025-02-17) |
|---|---|---|
| Total return | -96.1% | -98.8% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -96.2% | -92.9% |
| Volatility (annualized) | 219.5% | 191.3% |
| Max drawdown | -98.5% (Oct 2025→Sep 2026) | -99.6% (Mar 2025→Sep 2026) |

## Peers (Medical Distribution)
AHG (Akso Health Group) USD 1.3 +6.56% · HSIC (Henry Schein, Inc.) USD 84.96 -1.21% · CAH (Cardinal Health, Inc.) USD 249.57 -2.37% · COR (Cencora, Inc.) USD 331 -2.21% · MCK (McKesson Corporation) USD 1,000.77 -1.14%

## More
Full page: https://nexqual.com/MEDS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in MEDS's own 10-K filed 2026-03-20 (https://www.sec.gov/Archives/edgar/data/2030763/000149315226012004/form10-k.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | Pharmacy | "Pharmacy recognizes product revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers, when we transfer promised" |
| Partner | Wellgistics | "May 11, 2023, we entered into a Membership Interest Purchase Agreement with Wellgistics LLC and its owners, Strategix Global LLC, Nomad" |
| Partner | Strategix Global | "May 11, 2023, we entered into a Membership Interest Purchase Agreement with Wellgistics LLC and its owners, Strategix Global LLC, Nomad" |
| Partner | Amazon (AMZN) | "joint venture of Amazon, Berkshire Hathaway, and JPMorgan Chase) over recent years." |
| Partner | UPS (UPS) | "partners (i.e., Lyft and Roadie) for prescription delivery; and shipping carriers (i.e., USPS, UPS, FedEx), rising fuel costs will lead" |
| Partner | FedEx (FDX) | "partners (i.e., Lyft and Roadie) for prescription delivery; and shipping carriers (i.e., USPS, UPS, FedEx), rising fuel costs will lead" |
| Partner | Cencora (COR) | "Health's distribution agreement with AmerisourceBergen is subject to early termination in certain circumstances and, upon the expiration" |
| Partner | Wellgistics Health | "acquisition transactions and potential partnerships may also cause us to significantly increase Wellgistics Health's interest expense," |
| Partner | Datavault AI Inc. (DVLT) | "November 24, 2025, the Company entered into a License Agreement with Datavault AI Inc., pursuant to which the Company obtained a non-transferable" |
| Partner | Nomad Capital | "May 2023, we entered into a Membership Interest Purchase Agreement with Wellgistics LLC and its owners, Strategix Global LLC, Nomad Capital" |

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Pharmacy Retail Sales | $1.6M | 89.4% | +1945.3% |
| Third Party Logistics Services | $122,728 | 6.9% | -25.4% |
| Product | $66,765 | 3.8% | -99.1% |
| Total revenue | $1.8M | 100% | — |

## Customer concentration

Period ended 2026-06-30: 10% of revenue from unnamed direct customers (10-Q, filed 2026-08-17).

## Company outlook (8-K filed 2026-08-18)

- "The Company is expecting to launch the Health Lives Here (HLH) consumer app together with National Football League Alumni Health (NFLAH) in September 2026, targeting patients on or contemplating taking GLP-1 agonist medications in rural communities through their local independent pharmacies."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |